Dependency and transfer incomes in idiopathic Parkinson s disease

Similar documents
Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Appendix 2: Admissions checklists for people with Parkinson s

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Evaluation and Management of Parkinson s Disease in the Older Patient

Parkinson s Disease Current Treatment Options

Optimizing Clinical Communication in Parkinson s Disease:

Faculty. Joseph Friedman, MD

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Parkinson s Disease. Gillian Sare

Scottish Medicines Consortium

PARKINSON S MEDICATION

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

Movement Disorders: A Brief Overview

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

Medications used to treat Parkinson s disease

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW

New Medicines Committee Briefing July 2011

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Best Medical Treatments for Parkinson s disease

Parkinson s Disease. Sirilak yimcharoen

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth

Clinical Guideline for the management of inpatients with Parkinson s disease

Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

XADAGO (safinamide) oral tablet

Parkinson s disease: diagnosis and current management

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Parkinson s Disease Update

The Direct Cost of Parkinson Disease at Juntendo Medical University Hospital, Japan

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Clinical Features and Treatment of Parkinson s Disease

ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

Key Concepts and Issues in Parkinson s Disease in 2016

Commonly encountered medications and their side effects - what the generalist needs to know

Update on Parkinson s disease and other Movement Disorders October 2018

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

Final Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK

AMBULATORY UTILIZATION OF ANTI-PARKINSONIAN DRUGS IN ALBANIA DURING

Karen Tu MD, MSc, CCFP, FCFP Scientist ICES Associate Professor DFCM, University of Toronto Active Staff Toronto Western Hospital FHT

The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK

Welcome and Introductions

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease

Recent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Early Treatment Options When to start, what with, and why?

Dr Barry Snow. Neurologist Auckland District Health Board

10th Medicine Review Course st July Prakash Kumar

An Overview of Parkinson s Medication used in Multiple System Atrophy

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

What s new for diagnosing and treating Parkinson s Disease?

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Parkinson s Disease Medications: Professionals Edition

Evaluation of Parkinson s Patients and Primary Care Providers

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

BORDEAUX MDS WINTER SCHOOL FOR YOUNG

8/28/2017. Behind the Scenes of Parkinson s Disease

Clinical Trial Results Posting

An Overview of Parkinson s Medication used in Multiple System Atrophy

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006

Section 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

Acute management of in-patient Parkinson s Disease patients

Update in the Management of Parkinson s Disease

Continuous dopaminergic stimulation

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Drugs for Parkinson s Disease

Prior Authorization with Quantity Limit Program Summary

Safinamide: un farmaco innovativo con un duplice meccanismo d azione

What is Parkinson s Disease?

NMG-NEUROLOGY Dr. Bega, Dr. Malkani, Dr. Melen, Dr. Opal, Dr. Simuni, and Dr. Zadikoff MEDICAL BACKGROUND AND INFORMATION FORM

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Report on New Patented Drugs Azilect

Welcome and Introductions

Movement Disorders. Eric Kraus, MD! Neurology!

Parkinson s disease and primary care

Keywords: deep brain stimulation; subthalamic nucleus, subjective visual vertical, adverse reaction

Advances in Parkinson s Disease Treatment. Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Communicating About OFF Episodes With Your Doctor

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

Medication Management & Strategies When the levodopa honeymoon is over

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

III./3.1. Movement disorders with akinetic rigid symptoms

Transcription:

Dan Med J 61/10 October 2014 danish medical JOURNAL 1 Dependency and transfer incomes in idiopathic Parkinson s disease Charlotte Starhof 1, Niels Anker 2, Tove Henriksen 1 & Christina Funch Lassen 3 Abstract Introduction: Idiopathic Parkinson s disease (IPD) is a progressive neurodegenerative disorder affecting approximately 1% of the population above 65 years of age. The aim of this study was to define the estimated Danish IPD population and to elucidate source of income and labour market affiliation for working-age IPD patients. Material and methods: IPD cases were included through the Danish Register of Medicinal Product Statistics. The participants had to be alive by the end of 2010 and at least twice have cashed in prescriptions on IPD medication in the 2009-2010 period. Information on employment status and transfer income was retrieved through the DREAM database under the Danish Ministry of Employment. Results: A total of 7,033 estimated IPD patients were identified. The mean age at time of registration (2010, week 50) was 72 years. Overall, 7% of the IPD patients were employed and 5% were self-supportive. In the working age range (18-64 years), 25% were employed and 10% enrolled in supported employment. Compared with the age-adjusted general population, twice as many IPD patients were outside the ordinary labour market and, furthermore, the proportion receiving anticipatory pension was increased threefold. The majority (89%) of the patients were living at home with a spouse (59%). 11% were nursing home residents. Conclusion: The working age IPD population was more prone to be outside employment and to receive public transfer income than an age-adjusted population sample. Funding: The study was funded by the Danish Parkinson Association. Trial registration: not relevant. Idiopathic Parkinson s disease (IPD) is a progressive neuro degenerative disorder of unknown aetiology. Its prevalence is estimated to approximately 1% in the population above 65 years of age and increasing with age [1, 2]. The estimated number of Danish patients suffering from IPD is 6,000-8,000. The diagnosis is based on clinical criteria, and cardinal symptoms consists of bradykinesia in combination with resting tremor, rigidity and postural instability [3]. IPD is characterised by loss of dopaminergic neurons in the substantia nigra which results in decreased levels of dopamine. The response on motor symptoms to dopaminerge replacement therapy early in disease course is beneficial. As the disease progresses, patients experience increasing disability and morbidity. In addition to motor symptoms, patients suffering from IPD may also experience cognitive deficits which often include executive dysfunction (planning, initiation), attention and visuospatial perception as well as memory impairment [4]. Other non-motor symptoms include sleep disturbances, autonomic symptoms as well as co-incident depression. IPD is more prevalent among the elderly population, but IPD also affects younger individuals and individuals in the working age. The group of young-onset IPD patients has a high percentage of impairment of occupational performance and early retirement as well as psychosocial dysfunction [5]. In addition, both motor and non-motor symptoms may cause a reduction in working capacity, and IPD is generally associated with high socioeconomic costs, measured by direct and particularly by indirect costs, as well as a high degree of utilisation of health-care resources and an overall progressive impairment of health-related quality of life [6-10]. The aim of the present study was to define the estimated Danish IPD population, to investigate labour market affiliation for IPD patients in the working age and to elucidate source of income (public transfer incomes). Material and methods Relevant cases for this study were identified as all Danish citizens who collected anti-parkinson medication in relevant doses at a pharmacy during the study period. The study is register-based. This design was chosen to achieve a population-based approach and to ensure inclusion of patients in the early stages of disease. Participants were captured through the Danish Register of Medicinal Product Statistics. The register holds information on total sales of medicinal products since 1994 for the primary sector and in 1997 the register was extended to include hospital prescriptions. It is maintained by The State Serum Institute (SSI) and is updated on a monthly basis. In this study, only prescriptions handed out at Danish pharmacies are included. Participants had to be alive at the end of 2010 and to have redeemed a prescription twice or more for one of the medications shown in Table 1 in the 2009-2010 period. Prescriptions required an indication of Original article 1) Department of Neurology, Bispebjerg Hospital 2) COWI A/S, 2800 Lyngby, Denmark 3) The Danish Cancer Society Dan Med J 2014;61(10):A4915

2 danish medical JOURNAL Dan Med J 61/10 October 2014 TablE 1 Classification of pharmaceuticals. Classification Pharmaceutical Constituents ATC code Dosage Dopamine Duodopa Carbidopa, levodopa N04BA02 All Levodopa/carbidopa Carbidopa, levodopa N04BA02 2 doses/day Sinemet Carbidopa, levodopa N04BA02 2 doses/day Sinemet depot Carbidopa, levodopa N04BA02 2 doses/day Madopar Benserazid, levodopa N04BA02 2 doses/day Madopar depot Benserazid, levodopa N04BA02 2 doses/day Levodopa/benerazid Teva Benserazid, levodopa N04BA02 2 doses/day Stalevo Levodopa, carbidopa, entakapon N04BA03 All MAO-B inhibitors Azilect Rasagilin N04BD02 All Selegilin Selegilin N04BD01 All Eldepryl Selegilin N04BD01 All COMT inhibitors Comtan Entakapon N04BX02 All Comtess Entakapon N04BX02 All Tasmar Tolcapon N04BX01 All Dopamine agonists Apo-go Apomorfin N04BC07 All Pramipexol Pramipexol N04BC05 At least ½ tablet tds Pramipexol depot Pramipexol N04BC05 All Oprymea Pramipexol N04BC05 At least ½ tablet tds Oprymea depot Pramipexol N04BC05 All Cabaser Cabergolin N04BC06 2 mg/day Cabergolin Cabergolin N04BC06 2 mg/day Permax (expired 2011) Pergolid N04BC02 0.25 mg/day Pergolid (expired 2011) Pergolid N04BC02 0,25 mg/day Sifrol Pramipexol N04BC05 At least ½ tablet tds Sifrol depot pramipexol depot N04BC05 All Mirapexin Pramipexol N04BC05 At least ½ tablet tds Requip Ropinirol N04BC04 At least ½ tablet tds Requip depot ropinirol depot N04BC04 All Ropinirol Ropinirol N04BC04 At least ½ tablet tds Ropinirol depot Ropinirol N04BC04 All Neupro Rotigotin N04BC09 All COMT = catechol-o-methyltransferase; MAO = monoamine oxidase; tds = ter die sumendum (3 times a day). Parkinson s disease/parkinson-related dementia corresponding to indication code 351 or 595. Dopaminergic agents belong to ATC group N04B. As dopaminergic agents have a few other indications than IPD, such as restless legs syndrome and the rare condition of dopamine-responsive dystonia, cut-off values were used regarding daily dose and number of daily administrations. Criteria concerning classification of medication as well as dosage were established by movement disorder specialist TH. Cases who had only one redeemed prescription for anti-parkinson medication in the 2009-2010 period were excluded to avoid accidental errors in the register. Participants were cross-checked in the National Hospital Registry (NHR) by International Classification of Disease (ICD-10) code DG 20.9 (Parkinson s disease) between 1994 and 2010. Information on educational level was retrieved from the educational attainment statistics, information on marital status and residence through the Population Statistics Register and information on nursing home residents was retrieved through the Statistics Documentation of the Elderly under Statistics Denmark. Information on co-morbidity was evaluated though the NHR by ICD-10 classification registration for 2009 and 2010. Public transfer income Information on dependency status was generated though the DREAM database, which is a longitudinal data base within the National Labour Market Authority and Ministry of Employment holding information on Danish citizens receiving public transfer income with weekly follow-ups. The DREAM database was established in 1991 and link data from the Ministry of Employment, the Ministry of Education, the Central Civil Register and the Danish Customs and Tax Administration. Since 2008, the database also holds information on employment status. Data reflect the status of included patients in week 50, 2010. In order to compare data with the general popula-

Dan Med J 61/10 October 2014 danish medical JOURNAL 3 Profile of cases. TablE 2 Total, n 7,033 Gender, % Male 57 Female 43 Distribution on age, % a 18-39 yrs 0 40-49 yrs 2 50-59 yrs 9 60-64 yrs 11 65-69 yrs 16 70-74 yrs 19 75-79 yrs 19 80-84 yrs 14 85-89 yrs 7 90 yrs 2 Ethnicity, % Danish 96 Immigrants/descendants of immigrants 4 Education, % Elementary school 40 High-school 2 Vocational education 36 Higher education: Short-cycle 3 Medium-cycle 13 Long-cycle 6 Residency, % Nursing home 11 At home: 89 Living alone 30 Living with spouse 59 a) Distribution on age sums to 99% due to round-down. tion, corresponding data from a random sample including 20% of the Danish population were retrieved. An indirect age-standardisation was done within the group from 18 to 64 years of age to adjust for the distribution of age within the IPD group. All analyses were carried out by author NA who used the research facilities at the Statistics Denmark. Trial registration: not relevant. Results A total of 7,033 patients were identified through the Danish Register of Medicinal Product Statistics according to the established inclusion criteria. By linking the 7,033 cases with the NHR, 3,727 patients were identified as discharged from a hospital with a primary diagnosis of Parkinson s disease (DG20). For the remaining 3,306 patients, this was not the case. There were 4,009 men (57%) and 3,024 (43%) women. The mean age was 72 years. Data on their distribution on age, ethnicity, educational level, marital status and residency are presented in Table 2. Patients represent the elderly population, and 78% were above 65 years of age at the end of 2010 (week 50) and presumably retired from labour activities. A total of 2% were under the age of 50 years and in total 22% were in the working age (18-64 years). The patients level of education reflects the population in general taking into account their age profile. The majority (89%) were living at home with only 30% of these living alone. In total, 11% of the IPD patients were nursing home residents, although this only applies to 2% of those under 65 years of age. In the IPD population older than 65 years of age, 13% were nursing home residents. This number was 25% for patients above 80 years. The IPD patients have a high degree of co-morbidity, and 71% of the patients had a contact in 2009-2010 in the NHR distinct from DG20.9 concerning hospitalisation or treatment in an outpatient clinic. Income status and transfer income Overall, 5% of the IPD population was self-supportive and presumably employed, and an additional 2% were employed in supported employment. A total of 78% were receiving public retirement pension, and 9% were receiving anticipatory pension. 3% were receiving early retirement benefits. Sub-group analyses on the patient population (18-64 years) available to the labour market showed that 25% were self-supportive and 10% were employed in supported employment. A total of 43% were receiving an anticipatory pension. A small percentage (4%) was receiving sickness benefits, and 16% were enrolled in the early retirement programme. In total, 75% of the patients aged 18-64 years were receiving public transfer income. The highest proportion of self-supported patients divided by age was found in the age group from 40-49 years and 50-59 years with 31%, descending to 24% in the group under the age of 40 years and 19% over the age of 60 years. Statistics on employment compared with the Danish population in general are presented in Figure 1. A description of public transfer incomes is shown in Table 3. Although the proportion of anticipatory pension and supported employment recipients was higher, sickness benefits did not differ between the two groups. Sub-group analysis on the IPD population (18-64 years) registered in the NHR with an admission under DG 20 was less likely to be self-supportive (19%) and more likely to receive anticipatory pension (49%) than cases without an admission (34%). Discussion In this study, we evaluated the dependency status and

4 danish medical JOURNAL Dan Med J 61/10 October 2014 FigurE 1 Employment and dependency staus: IPD population and general population, 18-64 years. % 100 90 80 70 60 50 40 30 20 10 0 Self-supportive/ employed Sickness benefit Anticipatory pension Unemployment benefits Social security IPD population Age-adjusted general population IPD = idiopathic Parkinson s disease. Supported employment public transfer incomes in the estimated Danish IPD population. To our knowledge, this is the first time data on this issue have been presented. Results identify IPD as a disease that is mostly preva lent in the elderly population, which is reflected by the fact the majority of participants were receiving public retirement pension. Overall, 95% of the IPD patients were receiving public transfer income. Among working age persons, one third were affiliated to the labour market, but twice as many IPD patients were outside the ordinary labour market, and the proportion receiving anticipatory pension was increased three-fold compared with an age-adjusted population sample. In IPD patients with a prior IPD-related hospital admission, the proportion was even higher than in IPD patients with no admission. The marked difference in employment may not only be due to motor deficits and physical constraints. The neuropsychological and neuropsychiatric symptoms associated with IPD presumably contribute considerably, with cognitive impairment being among the most prevalent factors. A recent prospective study in a cohort of IPD patients found that age, duration of disease, morbidity (higher United Parkinson s Disease Rating Scale (UPDRS) score and Hoehn and Yeah stage) were associated with an increased risk of future loss of ability to work. The same study also reported a 3.5-fold increased Benefits Early retirement Other TablE 3 Description of transfer incomes. Transfer income Employed self-supported. No transfer payment a Public retirement pension b Sickness benefits c Anticipatory pension d Unemployment benefits e Social security f Supported employment g Benefits h Early retirement i Transfer income (Danish translation) I arbejde selvforsørgende Folkepension Sygedagpenge Førtidspension Dagpenge Kontanthjælp Fleksjob Ledighedsydelse Efterløn a) No public transfer income. Presumable the person is employed and self-supportive; b) A public benefit administered to Danish citizens over the age of 65 years; c) The patient is sick-listed by the employer and receiving sickness benefits. d) Anticipatory pension is a social security service provided to persons aged 18-64 years whose capacity to work is substantially reduced due to physical, mental or social reasons. e) The person is registered as unemployed by the Public Employment Service. In order to receive unemployment benefits, the patient has to be a member of an unemployment insurance fund. f) Social security is administered by the municipalities if the patient is unable to support him-/herself. g) Supported employed assist persons with disabilities in being able to be employed in the ordinary labour market on reduced time. h) Benefits covers a special benefit provided to persons who have been approved for supported employment, but who are not yet employed. i) The early retirement programme offers the opportunity to retire early. The programme is financed by the Danish state and personal contributions. risk of future loss of ability to work in patients with intellectual impairment at baseline [11]. Withdrawal from the labour market may presumably add to morbidity and may be connected with a decreased quality of life, social implications and may interfere with family life, especially in the young IPD patients [5]. Our results are in keeping with the few previously published studies concerning loss of employment and IPD. Hence, one study reported a mean age of retirement of 55.8 years in the IPD population available to the labour market compared with an overall populationbased retirement age of 62 years, and a mean time to loss of employment of 4.9 years from diagnosis [12]. The majority of IPD patients are living at home with a spouse or partner, and a total of 11% are nursing home residents. The need for care varies with disease stages. But since a substantial part of the IPD patients are living at home, a focus on the uncompensated caregivers within the family is important. One study evaluated the impact of living with an IPD patient on the uncompensated non-professional caregivers and found reduced life space and high frequencies of early retire-

Dan Med J 61/10 October 2014 danish medical JOURNAL 5 ment, sick leave and patient-care related part-time work [13]. Furthermore, an efficient home care nursing system is even more urgent in the part of the IPD population who are single and living at home. Diagnosing IPD can be challenging since the diagnosis relies on clinical criteria. Patients may have a shorter or longer preclinical period before being diagnosed with Parkinson s disease, and IPD has a broad range of differential diagnoses. IPD patients are being treated in different settings and can be followed in the primary sector (by a practicing neurologist or GP), in an outpatient clinic or in a tertiary centre such as a Movement Disorder Clinic. The patients are presumably most likely followed in the primary sector early in the uncomplicated stages of the disease. Inclusion through medical prescriptions was used to ensure inclusion of this segment of the IPD patients. This group is important to include as the group of patients early in disease is presumably more likely to be eligible to participate in labour-marked activities. Referring only to ICD-10 codes from hospital and outpatient clinics data would bias results towards the IPD group in late disease with increased severity of motor impairment and co-morbidity. Furthermore, some patients may be misclassified in the NHR. The study has several limitations. No medical record review of patients was performed. This caveat was dealt with by excluding patients with other indications than IPD on the prescription or with a dosage not likely to be compatible with IPD. Some IPD patients may be newly diagnosed and collected medication only once; and for some patients receiving dopaminergic medication in 2010, the diagnosis may later have been revised. No data were collected on the duration of disease, severity of disease and time of diagnosis to characterise the IPD group outside the labour market. Some patients suffering from atypical Parkinsonism, like multiple system atrophy, corticobasal degeneration, progressive supranuclear palsy or dementia with Lewy bodies, will be present in the material. These diseases are relatively infrequent and they are characterised by a poor Levodopa response, but also with an increased morbidity. Based on previous studies with review of medical journals on IPD patients, this group is believed to cause bias [14]. Furthermore, some patients may suffer from vascular Parkinsonism. The results were compared with the results of an age-adjusted population sample but not adjusted for gender. The authors are aware that since IPD it slightly more prevalent in men than in women in the present material, this will cause minor bias. In summary, IPD is a disease associated with high socio-economic costs, and the results of this study emphasised that IPD is associated with indirect costs due to loss of working capacity. Strategies to ensure optimal treatment in specialised outpatient clinics focusing on motor as well as non-motor symptoms, social aspects concerning family support and employment may help to improve health-related quality of life (HR-QOL) in IPD patients in the working age [7]. Data reflect the fact that IPD is a progressive disease with deficits that make it difficult for Parkinson patients to maintain an affiliation with the ordinary labour market. Conclusion Based on the Danish Register of Medicinal Product Statistics, the Danish IPD population is estimated to count 7,033 individuals in late 2010. IPD was associated with reduced affiliation with the labour market. Compared with the age-adjusted general population, twice as many IPD patients were outside the ordinary labour market and, furthermore, the proportion receiving anticipatory pension was increased three-fold. Correspondence: Christina Funch Lassen, Kræftens Bekæmpelse, Strandboulevarden 49, 2100 Copenhagen, Denmark. E-mail: funch@cancer.dk. Accepted: 28 July 2014 Conflicts of interest: Disclosure forms provided by the authors are available with the full text of this article at www.danmedj.dk Literature 1. Hirtz D, Thurman DJ, Gwinn-Hardy K et al. How common are the common neurologic disorders? Neurology 2007;68:326-37. 2. Gazewood JD, Richards DR, Clebak K. Parkinson disease: an update. Am Fam Physician 2013;87:267-73. 3. Gelb DJ. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56: 33-9. 4. Pagonabarraga J, Kulisevsky J. Cognitive impairment and dementia in Parkinson s disease. Neurobiol Dis 2012;46:590-6. 5. Schrag A, Hovris A, Morley D et al. Young- versus older-onset Parkinson s disease: impact of disease and psychosocial consequences. Mov Disord 2003;18:1250-6. 6. Gustavsson A, Svensson M, Jacobi F et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718-79. 7. Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson s disease. Drugs Aging 2006;23:693-721. 8. Schrag A, Jahanshahi M, Quinn N. How does Parkinson s disease affect quality of life? Mov Disord 2000;15:1112-8. 9. Huse DM, Schulman K, Orsini L et al. Burden of illness in Parkinson s disease. Mov Disord 2005;20:1449-54. 10. Johnson S, Davis M, Kaltenboeck A et al. Early retirement and income loss in patients with early and advanced Parkinson s disease. Appl Health Econ Health Policy 2011;9:367-76. 11. Jasinska-Myga B, Heckman MG, Wider C et al. Loss of ability to work and ability to live independently in Parkinson s disease. Parkinsonism Relat Disord 2012;18:130-5. 12. Schrag A, Banks P. Time of loss of employment in Parkinson s disease. Mov Disord 2006;21:1839-43. 13. Lökk J. Reduced life-space of non-professional caregivers to Parkinson s disease patients with increased disease duration. Clin Neurol Neurosurg 2009;111:583-7. 14. Wermuth L, Lassen CF, Himmerslev L et al. Validation of hospital registerbased diagnosis of Parkinson s disease. Dan Med J 2012;59(3):A4391.